Indapamide
Sulfonamides, Plain
Sold as COVERSYL PLUS · COVERSYL PLUS LD · COVERSYL PLUS HD
- Drug class
- Sulfonamides, Plain
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 68
- FDA reports (12 mo)
- 1,080
Overview
Plain-language summary, compiled from the cited regulatory records
Indapamide is a medication classified as a sulfonamide diuretic [1]. It is approved for treating high blood pressure, either on its own or in conjunction with other medications that lower blood pressure [1]. Indapamide is also indicated for managing fluid and salt retention in individuals experiencing congestive heart failure [1].
The routine use of diuretics during pregnancy in otherwise healthy women is not recommended, as it can pose unnecessary risks to both the mother and the fetus [1]. Diuretics are not effective in preventing the development of toxemia of pregnancy [1].
In the past 12 months, there have been 1080 adverse event reports associated with indapamide [2]. Among the frequently reported adverse events are acute kidney injury, low sodium levels (hyponatraemia), diarrhea, and joint pain (arthralgia) [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| CA Canada | Health Canada | 34 | May 13, 2026 |
| GB United Kingdom | MHRA | 33 | May 1, 2026 |
| US United States | FDA | 1 | June 26, 2023 |
CACanada· Health Canada
34 products
Uses
COVERSYL® PLUS LD (perindopril erbumine / indapamide) is indicated for the initial treatment of mild to moderate essential hypertension. COVERSYL® PLUS and COVERSYL® PLUS HD (perindopril erbumine / indapamide) are indicated in the treatment of mild to moderate essential hypertension in patients for whom combination therapy is appropriate.
COVERSYL® PLUS and COVERSYL® PLUS HD are not indicated for initial therapy. Patients in whom perindopril and indapamide are initiated simultaneously can develop symptomatic hypotension (see 9 DRUG INTERACTIONS – Drug-Drug Interactions - Concomitant ACE Inhibitor and Diuretic Therapy).
Patients should be titrated on the individual drugs. If the fixed combination represents the dosage determined by this titration, the use of COVERSYL® PLUS or COVERSYL® PLUS HD may prove to be more convenient in the management of patients.
If during maintenance therapy dosage adjustment is necessary, it is advisable to use individual drugs (see 4 DOSAGE AND ADMINISTRATION). The safety and efficacy of COVERSYL® PLUS LD / COVERSYL® PLUS / COVERSYL® PLUS HD in renovascular hypertension and in congestive heart failure have not been established and therefore, their use in this condition is not recommended.
GBUnited Kingdom· MHRA
33 products
Uses
Indapamide Teva is indicated in essential hypertension in adults.
How to take
USUnited States· FDA
1 product
Uses
INDICATIONS
Indapamide tablets are indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs. Indapamide tablets are also indicated for the treatment of salt and fluid retention associated with congestive heart failure.
Usage in Pregnancy :
The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard (see PRECAUTIONS below). Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia.
Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Indapamide is indicated in pregnancy when edema is due to pathologic causes, just as it is in the absence of pregnancy (however, see PRECAUTIONS below).
Drug interactions
Known interactions involving Indapamide. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 488. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]Health Canada (DPD) · 02246568 · revised March 22, 2025
- [2]MHRA (UK) · PL002891298 · revised October 17, 2025
- [3]FDA DailyMed · 0687ed93-4761-4f… · revised June 26, 2023 [PDF]
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.